Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Bladder cancer updates from the first half of 2026

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results

Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

The evolving treatment landscape in immune thrombocytopenia

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma